Lorne Steinberg Wealth Management Inc. Grows Stock Position in Smith & Nephew SNATS, Inc. (NYSE:SNN)

Lorne Steinberg Wealth Management Inc. boosted its position in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 12.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 262,405 shares of the medical equipment provider's stock after purchasing an additional 29,250 shares during the period. Smith & Nephew SNATS comprises approximately 2.2% of Lorne Steinberg Wealth Management Inc.'s portfolio, making the stock its 16th biggest holding. Lorne Steinberg Wealth Management Inc. owned 0.06% of Smith & Nephew SNATS worth $7,444,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Principal Securities Inc. raised its stake in shares of Smith & Nephew SNATS by 87.6% in the fourth quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider's stock valued at $36,000 after buying an additional 691 shares during the period. National Bank of Canada FI lifted its stake in shares of Smith & Nephew SNATS by 36.5% during the 4th quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock valued at $41,000 after buying an additional 446 shares in the last quarter. Hara Capital LLC lifted its stake in shares of Smith & Nephew SNATS by 391.4% during the 4th quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider's stock valued at $60,000 after buying an additional 1,957 shares in the last quarter. Opal Wealth Advisors LLC bought a new position in Smith & Nephew SNATS in the 1st quarter worth approximately $73,000. Finally, GAMMA Investing LLC grew its stake in Smith & Nephew SNATS by 22.4% in the 1st quarter. GAMMA Investing LLC now owns 3,641 shares of the medical equipment provider's stock valued at $103,000 after buying an additional 666 shares in the last quarter. 25.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

SNN has been the subject of several recent research reports. UBS Group cut Smith & Nephew SNATS from a "buy" rating to a "neutral" rating in a research report on Wednesday, March 12th. Canaccord Genuity Group lifted their price objective on Smith & Nephew SNATS from $27.00 to $28.00 and gave the company a "hold" rating in a research note on Thursday, May 1st. Hsbc Global Res cut Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. HSBC cut Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a report on Friday, April 25th. Finally, Wall Street Zen upgraded shares of Smith & Nephew SNATS from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, February 26th. Six research analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. According to MarketBeat.com, Smith & Nephew SNATS currently has an average rating of "Hold" and a consensus target price of $28.00.

Smith & Nephew SNATS Price Performance

Shares of NYSE SNN traded down $0.11 during trading hours on Thursday, reaching $28.53. 890,947 shares of the stock traded hands, compared to its average volume of 804,309. The company's 50-day simple moving average is $28.15 and its two-hundred day simple moving average is $26.90. The company has a market capitalization of $12.49 billion, a P/E ratio of 13.21, a price-to-earnings-growth ratio of 0.88 and a beta of 0.68. Smith & Nephew SNATS, Inc. has a 52-week low of $23.69 and a 52-week high of $31.72. The company has a quick ratio of 1.33, a current ratio of 2.89 and a debt-to-equity ratio of 0.62.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.